Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


|Includes: EPIRUS Biopharmaceuticals, Inc (EPRS)

Great news for Zalicus ZLCS shareholders, a recent PR released by Sanofi shows that the compound FOV1101 had positive Phase IIb results and is ready for Phase III.

This positive data was not originally announced in the initial Q3 report when Sanofi SNY explained they were going to sublicence the compound.

Any day now a Phase III start could trigger a 3 million dollar milestone payment from Sanofi with additional milestone payments of close to 40 million as well as tiered royalties from sales!

Full PR can be found here (link)

Therapeutic Area: Ophthalmology - Inflammatory diseases of the ocular surface, including allergic conjunctivitis (NYSE:AC) Anti-inflammatory and immuno-modulator Treatment of signs and symptoms of allergic conjunctivitis

Patent protection:

Patents expire in November 2026 (without patent extension)

US: patented

EU: patent pending

License from Zalicus,

Route of administration:

Topical (eye drops)

Development phase:

Ready to enter Phase 3 development in the US


Mechanism of action:

Planned indication:

Disclosure: I am long ZLCS.